New data show Roches Itovebi significantly extended survival in a certain type of HR-positive advanced breast cancer
The ItovebiTM (inavolisib)-based regimen reduced the risk of death by more than…
Immunotherapeutic Targets for Recurrent Medulloblastoma Receives $85K Grant from Brain Cancer Canada
TORONTO, May 28, 2025 (GLOBE NEWSWIRE) -- Brain Cancer Canada is proud…
ENHERTU Approved in the EU as First HER2 Directed Therapy for Patients with HR Positive, HER2 Low or HER2 Ultralow Metastatic Breast Cancer Following at Least One Endocrine Therapy
Based on DESTINY-Breast06 phase 3 trial results which showed ENHERTU demonstrated superiority…
Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension Presented at the American College of Cardiologys Annual Scientific Session & Expo (ACC.25)
– Lorundrostat 50 mg dose achieved a 15.4 mmHg absolute reduction and…
Research by City of Hope and Other Scientists May Help Patients Overcome Resistance to Chimeric Antigen Receptor (CAR) T Cell Therapy
Research on New System Published in Nature Biomedical Engineering Platform Engineers T…
Sparian Biosciences Announces Results from the Phase 1 Clinical Trial of First in Class Novel Arylepoxamide Receptor (AEAr) Agonist Analgesic SBS-1000
SBS-1000 was shown to be safe and well tolerated in healthy volunteers…
Idorsia is advancing the treatment of hypertension with new data at the 2024 American Heart Association (AHA) Scientific Sessions
Allschwil, Switzerland – November 11, 2024 Idorsia Ltd (SIX: IDIA) today announced…
Corvus Pharmaceuticals Announces New Data Highlighting Potential of Ciforadenant to Overcome Immunotherapy Resistance in Metastatic Castration Resistant Prostate Cancer
Data presented in an oral session at the Society for Immunotherapy of…